Market Analysis and Insights: Global Alpha 1 Antitrypsin Deficiency Treatment Market
The research report studies the Alpha 1 Antitrypsin Deficiency Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Alpha 1 Antitrypsin Deficiency Treatment market size is projected to reach US$ 1720.4 million by 2027, from US$ 1177.9 million in 2020, at a CAGR of 5.1% during 2021-2027.
Global Alpha 1 Antitrypsin Deficiency Treatment Scope and Segment
The global Alpha 1 Antitrypsin Deficiency Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alpha 1 Antitrypsin Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
by Application, this report covers the following segments
Hospitals
Specialty Clinics
Pharmacies
Global Alpha 1 Antitrypsin Deficiency Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Alpha 1 Antitrypsin Deficiency Treatment key players in this market include:
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Applied Genetic Technologies
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Curaxys
ProMetic Life Sciences
The research report studies the Alpha 1 Antitrypsin Deficiency Treatment market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global Alpha 1 Antitrypsin Deficiency Treatment market size is projected to reach US$ 1720.4 million by 2027, from US$ 1177.9 million in 2020, at a CAGR of 5.1% during 2021-2027.
Global Alpha 1 Antitrypsin Deficiency Treatment Scope and Segment
The global Alpha 1 Antitrypsin Deficiency Treatment market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Alpha 1 Antitrypsin Deficiency Treatment market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2016-2027.
by Type, the market is primarily split into
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
by Application, this report covers the following segments
Hospitals
Specialty Clinics
Pharmacies
Global Alpha 1 Antitrypsin Deficiency Treatment market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The Alpha 1 Antitrypsin Deficiency Treatment key players in this market include:
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Takeda
LFB Biomedicaments
Abeona Therapeutics
Biogen
Applied Genetic Technologies
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Curaxys
ProMetic Life Sciences
1 Market Overview of Alpha 1 Antitrypsin Deficiency Treatment
1.1 Alpha 1 Antitrypsin Deficiency Treatment Market Overview
1.1.1 Alpha 1 Antitrypsin Deficiency Treatment Product Scope
1.1.2 Alpha 1 Antitrypsin Deficiency Treatment Market Status and Outlook
1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2016-2021)
1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
2 Alpha 1 Antitrypsin Deficiency Treatment Market Overview by Type
2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Type (2016-2021)
2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2022-2027)
2.4 Augmentation Therapy
2.5 Bronchodilators
2.6 Corticosteroids
2.7 Oxygen Therapy
3 Alpha 1 Antitrypsin Deficiency Treatment Market Overview by Application
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Application (2016-2021)
3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2022-2027)
3.4 Hospitals
3.5 Specialty Clinics
3.6 Pharmacies
4 Alpha 1 Antitrypsin Deficiency Treatment Competition Analysis by Players
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2020)
4.3 Date of Key Players Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
4.4 Global Top Players Alpha 1 Antitrypsin Deficiency Treatment Headquarters and Area Served
4.5 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Pfizer Recent Developments
5.2 Baxter
5.2.1 Baxter Profile
5.2.2 Baxter Main Business
5.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.2.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Baxter Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Grifols Recent Developments
5.4 Grifols
5.4.1 Grifols Profile
5.4.2 Grifols Main Business
5.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.4.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Grifols Recent Developments
5.5 Teva Pharmaceutical Industries
5.5.1 Teva Pharmaceutical Industries Profile
5.5.2 Teva Pharmaceutical Industries Main Business
5.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Teva Pharmaceutical Industries Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.6.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Kamada Ltd
5.7.1 Kamada Ltd Profile
5.7.2 Kamada Ltd Main Business
5.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.7.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Kamada Ltd Recent Developments
5.8 GlaxoSmithKline
5.8.1 GlaxoSmithKline Profile
5.8.2 GlaxoSmithKline Main Business
5.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.8.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 GlaxoSmithKline Recent Developments
5.9 CSL Behring
5.9.1 CSL Behring Profile
5.9.2 CSL Behring Main Business
5.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 CSL Behring Recent Developments
5.10 Takeda
5.10.1 Takeda Profile
5.10.2 Takeda Main Business
5.10.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.10.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Takeda Recent Developments
5.11 LFB Biomedicaments
5.11.1 LFB Biomedicaments Profile
5.11.2 LFB Biomedicaments Main Business
5.11.3 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.11.4 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 LFB Biomedicaments Recent Developments
5.12 Abeona Therapeutics
5.12.1 Abeona Therapeutics Profile
5.12.2 Abeona Therapeutics Main Business
5.12.3 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.12.4 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 Abeona Therapeutics Recent Developments
5.13 Biogen
5.13.1 Biogen Profile
5.13.2 Biogen Main Business
5.13.3 Biogen Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.13.4 Biogen Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 Biogen Recent Developments
5.14 Applied Genetic Technologies
5.14.1 Applied Genetic Technologies Profile
5.14.2 Applied Genetic Technologies Main Business
5.14.3 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.14.4 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.14.5 Applied Genetic Technologies Recent Developments
5.15 Baxalta
5.15.1 Baxalta Profile
5.15.2 Baxalta Main Business
5.15.3 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.15.4 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.15.5 Baxalta Recent Developments
5.16 Arrowhead Research Corporation
5.16.1 Arrowhead Research Corporation Profile
5.16.2 Arrowhead Research Corporation Main Business
5.16.3 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.16.4 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.16.5 Arrowhead Research Corporation Recent Developments
5.17 ProBioGen
5.17.1 ProBioGen Profile
5.17.2 ProBioGen Main Business
5.17.3 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.17.4 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.17.5 ProBioGen Recent Developments
5.18 Chiesi Pharmaceuticals
5.18.1 Chiesi Pharmaceuticals Profile
5.18.2 Chiesi Pharmaceuticals Main Business
5.18.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.18.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.18.5 Chiesi Pharmaceuticals Recent Developments
5.19 Curaxys
5.19.1 Curaxys Profile
5.19.2 Curaxys Main Business
5.19.3 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.19.4 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.19.5 Curaxys Recent Developments
5.20 ProMetic Life Sciences
5.20.1 ProMetic Life Sciences Profile
5.20.2 ProMetic Life Sciences Main Business
5.20.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.20.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.20.5 ProMetic Life Sciences Recent Developments
6 North America
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
11.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
11.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
11.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
11.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 Alpha 1 Antitrypsin Deficiency Treatment Market Overview
1.1.1 Alpha 1 Antitrypsin Deficiency Treatment Product Scope
1.1.2 Alpha 1 Antitrypsin Deficiency Treatment Market Status and Outlook
1.2 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Overview by Region 2016 VS 2021VS 2027
1.3 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
1.4 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Region (2016-2021)
1.5 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size Forecast by Region (2022-2027)
1.6 Key Regions, Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.2 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.3 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.4 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
1.6.5 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size (2016-2027)
2 Alpha 1 Antitrypsin Deficiency Treatment Market Overview by Type
2.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Type: 2016 VS 2021 VS 2027
2.2 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Type (2016-2021)
2.3 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Type (2022-2027)
2.4 Augmentation Therapy
2.5 Bronchodilators
2.6 Corticosteroids
2.7 Oxygen Therapy
3 Alpha 1 Antitrypsin Deficiency Treatment Market Overview by Application
3.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Application: 2016 VS 2021 VS 2027
3.2 Global Alpha 1 Antitrypsin Deficiency Treatment Historic Market Size by Application (2016-2021)
3.3 Global Alpha 1 Antitrypsin Deficiency Treatment Forecasted Market Size by Application (2022-2027)
3.4 Hospitals
3.5 Specialty Clinics
3.6 Pharmacies
4 Alpha 1 Antitrypsin Deficiency Treatment Competition Analysis by Players
4.1 Global Alpha 1 Antitrypsin Deficiency Treatment Market Size by Players (2016-2021)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Alpha 1 Antitrypsin Deficiency Treatment as of 2020)
4.3 Date of Key Players Enter into Alpha 1 Antitrypsin Deficiency Treatment Market
4.4 Global Top Players Alpha 1 Antitrypsin Deficiency Treatment Headquarters and Area Served
4.5 Key Players Alpha 1 Antitrypsin Deficiency Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Alpha 1 Antitrypsin Deficiency Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Pfizer
5.1.1 Pfizer Profile
5.1.2 Pfizer Main Business
5.1.3 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.1.4 Pfizer Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.1.5 Pfizer Recent Developments
5.2 Baxter
5.2.1 Baxter Profile
5.2.2 Baxter Main Business
5.2.3 Baxter Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.2.4 Baxter Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.2.5 Baxter Recent Developments
5.3 AstraZeneca
5.3.1 AstraZeneca Profile
5.3.2 AstraZeneca Main Business
5.3.3 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.3.4 AstraZeneca Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.3.5 Grifols Recent Developments
5.4 Grifols
5.4.1 Grifols Profile
5.4.2 Grifols Main Business
5.4.3 Grifols Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.4.4 Grifols Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.4.5 Grifols Recent Developments
5.5 Teva Pharmaceutical Industries
5.5.1 Teva Pharmaceutical Industries Profile
5.5.2 Teva Pharmaceutical Industries Main Business
5.5.3 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.5.4 Teva Pharmaceutical Industries Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.5.5 Teva Pharmaceutical Industries Recent Developments
5.6 Boehringer Ingelheim
5.6.1 Boehringer Ingelheim Profile
5.6.2 Boehringer Ingelheim Main Business
5.6.3 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.6.4 Boehringer Ingelheim Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.6.5 Boehringer Ingelheim Recent Developments
5.7 Kamada Ltd
5.7.1 Kamada Ltd Profile
5.7.2 Kamada Ltd Main Business
5.7.3 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.7.4 Kamada Ltd Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.7.5 Kamada Ltd Recent Developments
5.8 GlaxoSmithKline
5.8.1 GlaxoSmithKline Profile
5.8.2 GlaxoSmithKline Main Business
5.8.3 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.8.4 GlaxoSmithKline Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.8.5 GlaxoSmithKline Recent Developments
5.9 CSL Behring
5.9.1 CSL Behring Profile
5.9.2 CSL Behring Main Business
5.9.3 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.9.4 CSL Behring Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.9.5 CSL Behring Recent Developments
5.10 Takeda
5.10.1 Takeda Profile
5.10.2 Takeda Main Business
5.10.3 Takeda Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.10.4 Takeda Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.10.5 Takeda Recent Developments
5.11 LFB Biomedicaments
5.11.1 LFB Biomedicaments Profile
5.11.2 LFB Biomedicaments Main Business
5.11.3 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.11.4 LFB Biomedicaments Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.11.5 LFB Biomedicaments Recent Developments
5.12 Abeona Therapeutics
5.12.1 Abeona Therapeutics Profile
5.12.2 Abeona Therapeutics Main Business
5.12.3 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.12.4 Abeona Therapeutics Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.12.5 Abeona Therapeutics Recent Developments
5.13 Biogen
5.13.1 Biogen Profile
5.13.2 Biogen Main Business
5.13.3 Biogen Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.13.4 Biogen Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.13.5 Biogen Recent Developments
5.14 Applied Genetic Technologies
5.14.1 Applied Genetic Technologies Profile
5.14.2 Applied Genetic Technologies Main Business
5.14.3 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.14.4 Applied Genetic Technologies Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.14.5 Applied Genetic Technologies Recent Developments
5.15 Baxalta
5.15.1 Baxalta Profile
5.15.2 Baxalta Main Business
5.15.3 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.15.4 Baxalta Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.15.5 Baxalta Recent Developments
5.16 Arrowhead Research Corporation
5.16.1 Arrowhead Research Corporation Profile
5.16.2 Arrowhead Research Corporation Main Business
5.16.3 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.16.4 Arrowhead Research Corporation Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.16.5 Arrowhead Research Corporation Recent Developments
5.17 ProBioGen
5.17.1 ProBioGen Profile
5.17.2 ProBioGen Main Business
5.17.3 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.17.4 ProBioGen Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.17.5 ProBioGen Recent Developments
5.18 Chiesi Pharmaceuticals
5.18.1 Chiesi Pharmaceuticals Profile
5.18.2 Chiesi Pharmaceuticals Main Business
5.18.3 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.18.4 Chiesi Pharmaceuticals Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.18.5 Chiesi Pharmaceuticals Recent Developments
5.19 Curaxys
5.19.1 Curaxys Profile
5.19.2 Curaxys Main Business
5.19.3 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.19.4 Curaxys Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.19.5 Curaxys Recent Developments
5.20 ProMetic Life Sciences
5.20.1 ProMetic Life Sciences Profile
5.20.2 ProMetic Life Sciences Main Business
5.20.3 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Products, Services and Solutions
5.20.4 ProMetic Life Sciences Alpha 1 Antitrypsin Deficiency Treatment Revenue (US$ Million) & (2016-2021)
5.20.5 ProMetic Life Sciences Recent Developments
6 North America
6.1 North America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Alpha 1 Antitrypsin Deficiency Treatment Market Size by Region (2016-2027)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Alpha 1 Antitrypsin Deficiency Treatment Market Size by Country (2016-2027)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Alpha 1 Antitrypsin Deficiency Treatment Market Dynamics
11.1 Alpha 1 Antitrypsin Deficiency Treatment Industry Trends
11.2 Alpha 1 Antitrypsin Deficiency Treatment Market Drivers
11.3 Alpha 1 Antitrypsin Deficiency Treatment Market Challenges
11.4 Alpha 1 Antitrypsin Deficiency Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
